TUSTIN, Calif.--(BUSINESS WIRE)--Dec. 7, 1998--Techniclone Corporation (Nasdaq:TCLN - news) a developer of leading-edge unique therapeutics for the advanced treatment of cancer, announced today that the Company has begun treating the first patient in its Phase II multi-center
human clinical study of its Tumor Necrosis Therapy (TNT) that is being investigated for the treatment of malignant glioma (brain cancer). The Phase II clinical study has a planned enrollment of 40 patients and the Company anticipates conducting this study at four clinical sites throughout the U.S.:
The Medical University of South Carolina (MUSC), University of California, San Francisco Medical Center (UCSF), Temple University and University of Utah.
As announced previously, Techniclone plans to recruit one-half of the study population from patients with newly diagnosed glioblastoma multiform (GBM) and the other half from patients with recurrent
(GBM) or anaplastic astrocytoma (AA) in these Phase II trials. The protocol also allows patients to receive two doses administered eight weeks apart with dosage for each patient to be individualized based on a unique algorithm developed by Techniclone during the Phase I investigation, which was completed in October, 1998.
''We are very excited to be associated with four clinical centers which are worldwide renowned research organizations,'' stated Dr. Jamie Oliver, Vice President of Clinical and Regulatory Affairs.
''Additionally, the allowance to treat our first patients with newly diagnosed forms of glioblastoma represent significant milestones in the progress we have made with TNT.'' |
